CCHF Virtual Merck Lecture Series

     Biocatalysis at Merck aims to change the way pharmaceuticals are manufactured.  The department's mission is to deliver manufacturing processes that are lower in cost and more sustainable, and that allow for supply chain simplification and inventory efficiency.  We proactively identify and develop the most impactful new biocatalytic technologies based on the needs of the company.  The most recent success story is the manufacturing synthesis of Merck's largest-selling product, sitagliptin (Januvia®).  This talk will present a history of biocatalysis at Merck, as well as insights into the future of biocatalysis in pharmaceutical manufacturing.

References:

1. Turner NJ, Truppo MD. Biocatalysis Enters a New Era. Curr Opin Chem Biol. 2013;17:212.

2. Truppo MD, Strotman H, Hughes G. Development of an Immobilized Transaminase Capable of Operating in Organic Solvent. ChemCatChem. 2012;4:1071.

3. Truppo MD, Hughes G. Development of an Improved Immobilized CAL-B for the Enzymatic Resolution of a Key Intermediate to Odanacatib. Org Process Res Dev. 2011;15:1033.

4. Savile CK, Janey JM, Mundorff EC, Moore JC, Tam S, Jarvis WR, et al. Biocatalytic Asymmetric Synthesis of Chiral Amines from Ketones Applied to Sitagliptin Manufacture. S